At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 331 enrolled
Drug / intervention
23-valent pneumococcal polysaccharide vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Revaccinations in the Elderly
In Brief
A Phase 4 clinical trial evaluating 23-valent pneumococcal polysaccharide vaccine for Vaccination. Completed, enrolled 331 participants across 1 site.
Detailed Summary
To evaluate the the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccination
CountriesChina
CollaboratorsSichuan Center for Disease Control and Prevention
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMar 2021
Primary CompletionDec 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedJan 8, 2021
Enrollment StartMar 30, 2021
Primary CompletionDec 20, 2021
Study CompletionFeb 15, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.5 years ago
Interventions
23-valent pneumococcal polysaccharide vaccinebiological
The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.